Kwon Youngmin, Hu Xin, Shi Kewei Sylvia, Zhao Jingxuan, Jiang Changchuan, Fan Qinjin, Han Xuesong, Zheng Zhiyuan, Warren Joan L, Yabroff K Robin
Department of Health Policy, Vanderbilt University Medical Center, Nashville, Tennessee.
American Cancer Society, Atlanta, Georgia.
JAMA Health Forum. 2025 Feb 7;6(2):e245436. doi: 10.1001/jamahealthforum.2024.5436.
IMPORTANCE: Considerable efforts have been dedicated to improving the quality of end-of-life care among patients with advanced cancer in the past decade. Whether the quality has shifted in response to these efforts remains unknown. OBJECTIVE: To examine contemporary patterns of end-of-life care among patients with advanced cancer. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study used a recent linkage of Surveillance, Epidemiology, and End Results and Medicare data to characterize patterns of end-of-life care. The cohort included fee-for-service Medicare decedents aged 66 years or older who were originally diagnosed with distant-stage breast, prostate, pancreatic, or lung cancers and died between 2014 and 2019. Analyses were conducted between June 1, 2023, and July 31, 2024. MAIN OUTCOMES AND MEASURES: Outcomes included monthly use of acute care, systemic therapy, and supportive care (ie, palliative and hospice care and advanced care planning) in the last 6 months of life. Additionally, a claims-based indicator was evaluated of potentially aggressive care in the last 30 days of life, defined as experiencing more than 1 acute care visit, in-hospital mortality, late receipt of systemic therapy, or hospice entry. RESULTS: The study included 33 744 Medicare decedents with advanced cancer (mean [SD] age, 75.7 [6.9] years; 52.1% male). From 6 months before death to month of death, there was an increase in the mean (SE) number of acute care visits (from 14.0 [0.5] to 46.2 [0.5] per 100 person-months), hospice use (from 6.6 [0.4] to 73.5 [0.5] per 100 person-months), palliative care (from 2.6 [0.2] to 26.1 [0.6] per 100 person-months), and advanced care planning (from 1.7 [0.6] to 12.8 [1.1] per 100 person-months). Overall, 45.0% of decedents experienced any indicator of potentially aggressive care. CONCLUSIONS AND RELEVANCE: This study found persistent patterns of potentially aggressive care, but low uptake of supportive care, among Medicare decedents with advanced cancer. A multifaceted approach targeting patient-, physician-, and system-level factors associated with potentially aggressive care is imperative for improving quality of care at the end of life.
重要性:在过去十年中,人们付出了巨大努力来提高晚期癌症患者的临终关怀质量。这些努力是否使质量发生了变化仍不清楚。 目的:研究晚期癌症患者临终关怀的当代模式。 设计、背景和参与者:这项回顾性队列研究利用了监测、流行病学和最终结果与医疗保险数据的最新关联来描述临终关怀模式。该队列包括66岁及以上按服务收费的医疗保险逝者,他们最初被诊断患有远处转移的乳腺癌、前列腺癌、胰腺癌或肺癌,并于2014年至2019年期间死亡。分析于2023年6月1日至2024年7月31日进行。 主要结局和指标:结局包括生命最后6个月中急性护理、全身治疗和支持性护理(即姑息和临终关怀以及高级护理计划)的月度使用情况。此外,还评估了一个基于索赔的指标,即生命最后30天内潜在的积极治疗,定义为经历超过1次急性护理就诊、住院死亡率、全身治疗延迟接受或临终关怀入院。 结果:该研究纳入了33744名患有晚期癌症的医疗保险逝者(平均[标准差]年龄为75.7[6.9]岁;52.1%为男性)。从死亡前6个月到死亡当月,每100人月的急性护理就诊平均(标准误)次数增加(从14.0[0.5]增至46.2[0.5]),临终关怀使用次数增加(从6.6[0.4]增至73.5[0.5]),姑息治疗次数增加(从2.6[0.2]增至26.1[0.6]),高级护理计划次数增加(从1.7[0.6]增至12.8[1.1])。总体而言,45.0%的逝者经历了任何潜在积极治疗的指标。 结论与意义:本研究发现,在患有晚期癌症的医疗保险逝者中,存在潜在积极治疗的持续模式,但支持性护理的接受率较低。针对与潜在积极治疗相关的患者、医生和系统层面因素采取多方面方法,对于提高临终关怀质量至关重要。
JAMA Health Forum. 2025-2-7
J Natl Cancer Inst. 2011-5-18
J Evid Based Integr Med. 2025
CA Cancer J Clin. 2025
J Clin Oncol. 2024-7-1
J Pain Symptom Manage. 2024-5
CA Cancer J Clin. 2024
Health Aff (Millwood). 2023-11
Am J Cancer Res. 2023-9-15
Oncologist. 2023-9-7
Nat Rev Drug Discov. 2023-8
JAMA Health Forum. 2023-5-5